Suppr超能文献

可逆赖氨酸靶向探针揭示基于停留时间的激酶选择性。

Reversible lysine-targeted probes reveal residence time-based kinase selectivity.

机构信息

Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA.

Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.

出版信息

Nat Chem Biol. 2022 Sep;18(9):934-941. doi: 10.1038/s41589-022-01019-1. Epub 2022 May 19.

Abstract

The expansion of the target landscape of covalent inhibitors requires the engagement of nucleophiles beyond cysteine. Although the conserved catalytic lysine in protein kinases is an attractive candidate for a covalent approach, selectivity remains an obvious challenge. Moreover, few covalent inhibitors have been shown to engage the kinase catalytic lysine in animals. We hypothesized that reversible, lysine-targeted inhibitors could provide sustained kinase engagement in vivo, with selectivity driven in part by differences in residence time. By strategically linking benzaldehydes to a promiscuous kinase binding scaffold, we developed chemoproteomic probes that reversibly and covalently engage >200 protein kinases in cells and mice. Probe-kinase residence time was dramatically enhanced by a hydroxyl group ortho to the aldehyde. Remarkably, only a few kinases, including Aurora A, showed sustained, quasi-irreversible occupancy in vivo, the structural basis for which was revealed by X-ray crystallography. We anticipate broad application of salicylaldehyde-based probes to proteins that lack a druggable cysteine.

摘要

靶向共价抑制剂的靶标范围的扩大需要涉及半胱氨酸以外的亲核试剂。尽管蛋白激酶中保守的催化赖氨酸是共价方法的一个有吸引力的候选物,但选择性仍然是一个明显的挑战。此外,很少有共价抑制剂已被证明能在动物中与激酶的催化赖氨酸结合。我们假设可逆的、针对赖氨酸的抑制剂可以在体内提供持续的激酶结合,其选择性部分由停留时间的差异驱动。通过将苯甲醛策略性地连接到一个混杂的激酶结合支架上,我们开发了化学蛋白质组学探针,这些探针可以在细胞和小鼠中可逆且共价地结合超过 200 种蛋白激酶。醛基邻位的羟基极大地增强了探针-激酶的停留时间。值得注意的是,只有少数激酶,包括 Aurora A,在体内表现出持续的、准不可逆的占据,其结构基础通过 X 射线晶体学揭示。我们预计基于水杨醛的探针将广泛应用于缺乏可成药半胱氨酸的蛋白质。

相似文献

6
Reactive Chemical Probes: Beyond the Kinase Cysteinome.反应性化学探针:超越蛋白激酶半胱氨酸组。
Angew Chem Int Ed Engl. 2018 Jul 20;57(30):9220-9223. doi: 10.1002/anie.201802693. Epub 2018 Jun 12.
9
The Cysteinome of Protein Kinases as a Target in Drug Development.蛋白激酶半胱氨酸组作为药物开发的靶点。
Angew Chem Int Ed Engl. 2018 Apr 9;57(16):4372-4385. doi: 10.1002/anie.201707875. Epub 2018 Feb 2.
10
Lysine-Targeted Inhibitors and Chemoproteomic Probes.赖氨酸靶向抑制剂和化学蛋白质组探针。
Annu Rev Biochem. 2019 Jun 20;88:365-381. doi: 10.1146/annurev-biochem-061516-044805. Epub 2019 Jan 11.

引用本文的文献

5
Advancing Covalent Ligand and Drug Discovery beyond Cysteine.超越半胱氨酸推进共价配体与药物发现
Chem Rev. 2025 Jul 23;125(14):6653-6684. doi: 10.1021/acs.chemrev.5c00001. Epub 2025 May 22.
10
Covalent Proximity Inducers.共价接近诱导剂
Chem Rev. 2025 Jan 8;125(1):326-368. doi: 10.1021/acs.chemrev.4c00570. Epub 2024 Dec 18.

本文引用的文献

1
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor.使用CDK2/4/6抑制剂扩大对肿瘤细胞周期的控制。
Cancer Cell. 2021 Oct 11;39(10):1404-1421.e11. doi: 10.1016/j.ccell.2021.08.009. Epub 2021 Sep 13.
4
KRAS Inhibition with Sotorasib in Advanced Solid Tumors.索托拉西布治疗晚期实体瘤的 KRAS 抑制作用。
N Engl J Med. 2020 Sep 24;383(13):1207-1217. doi: 10.1056/NEJMoa1917239. Epub 2020 Sep 20.
7
Discovery of Lysine-Targeted eIF4E Inhibitors through Covalent Docking.赖氨酸靶向 eIF4E 抑制剂的共价对接发现。
J Am Chem Soc. 2020 Mar 18;142(11):4960-4964. doi: 10.1021/jacs.9b10377. Epub 2020 Mar 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验